Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Phase 2 data of OGX-427(Apatorsen) Borealis-2 trial for advanced or metastatic bladder cancer due fourth quarter 2016

Source Link:: http://ir.oncogenex.com/releasedetail.cfm?ReleaseID=946232

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

OGXI

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details "We are pleased with the DSMB's recommendation to continue the Borealis-2 trial and we look forward to final results expected in 2016," said Scott Cormack, President and Chief Executive Officer of OncoGenex. "Additionally, early next year we will receive regulatory feedback on our apatorsen clinical trial design and development strategy for patients with non-muscle invasive bladder cancer."

http://ir.oncogenex....

Additional Relevant Details Update on 9.13.16: Announcing results from the Borealis-2™ trial, an investigator-sponsored, randomized phase 2 trial evaluating apatorsen in combination with docetaxel treatment compared to docetaxel treatment alone in patients with advanced or metastatic bladder cancer. Final results are expected in the fourth quarter of 2016.

http://ir.oncogenex....

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Oct 25, 2016

Occurred Source:

http://ir.oncogenex.com/releasedetail.cfm?ReleaseID=995427

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2 Top-line Data, Ogx-427, Borealis-2 Trial, Advanced Or Metastatic Bladder Cancer, Apatorsen